When was Lentigen founded?

Lentigen was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Where is Lentigen located?

Lentigen is headquartered in Gaithersburg, United States.

How many employees does Lentigen have?

As of Jan 31, 2026, the latest employee count at Lentigen is 21.

Is Lentigen a funded company?

Lentigen is a funded company, having raised an undisclosed amount across 12 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 30, 2005.

When was the latest funding round of Lentigen?

Lentigen's latest funding was a $***** Grant (prize money) round on Nov 04, 2010, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.17B in funding in 2026 to date.

Where does Lentigen rank among its competitors?

Lentigen ranks 58th amongst 82 active competitors, of which 30 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of Lentigen?

Lentigen's top competitors include Genedit, LogicBio and Portal. Among them, SonoThera secured the most recent funding round in June, 2026.

Lentigen - 2026 Company Profile, Funding & Competitors

Lentigen is an acqui-hired company based in Gaithersburg (United States), founded in 2004. It operates as a Developer of lentiviral vectors for pre-clinical and clinical applications. Lentigen has raised an undisclosed amount in funding. The company has 82 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like Genedit, LogicBio and Portal.

Company Details

Developer of lentiviral vectors for pre-clinical and clinical applications. It provides lentiviral vector manufacturing for translational research applications that include Multi-Lentiviral vector evaluation for evaluating constructs; custom concentrated for a feasibility study and custom chromatography purified for process evaluation.

Website: lentigen.com/home/
Social

Key Metrics

Founded Year

2004

Location

Gaithersburg, United States

Stage

Acqui-Hired

Latest Funding Round

Grant (prize money), Nov 04, 2010, $*****

Investors

Biomark Capital & 1 more

Ranked

58^th among 82 active competitors

Employee Count

21 as on Jan 31, 2026

Investment & Acquisitions

Living Pharma

Similar Companies

Genedit & 104 more

View Lentigen's full profile

Lentigen has raised funding over 12 rounds. Its first funding round was on Nov 30, 2005. Lentigen has 2 institutional investors.

Here is the list of recent funding rounds of Lentigen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 04, 2010	1640802	Grant (prize money)	3858446	3756224	6412045	8635878
Sep 30, 2010	4396842	Grant (prize money)	5772003	5545029	9189003	HHS
Jun 16, 2010	9924057	Grant (prize money)	6168331	2046123	2018643	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Lentigen's funding rounds and investors

Lentigen's employee count trend

Lentigen has 21 employees as of Jan 26. Here is Lentigen's employee count trend over the years:

Uncover Lentigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lentigen include Genedit, LogicBio and Portal. Here is the list of Top 10 competitors of Lentigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
2nd	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Andera Partners & 6 others	61/100
3rd	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	Pear VC, NFX & 7 others	60/100
4th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 3 others	58/100
5th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Vida Ventures, Arch Venture Partners & 21 others	57/100
6th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100
7th	ExpreS2ion Biotechnologies 2010, Copenhagen (Denmark), Public	Provider of recombinant protein production using an insect expression platform	-	Modelio Equity, Gemstone Capital & 2 others	53/100
8th	VIVEbiotech 2015, San Sebastian (Spain), Seed	Developer and manufacturer of lentiviral vectors	$3.86M	Inveready, Easo Ventures & 1 others	52/100
9th	Lysogene 2009, Neuilly sur seine (France), Public	Developer of gene therapies for neurodegenerative lysosomal storage disorders	$22.6M	Sofinnova Partners, Novo Holdings & 3 others	51/100
10th	Feldan 2007, Quebec City (Canada), Series B	Developing delivery system of proteins inside cells directly	$52.9M	Amgen, Invest Quebec & 12 others	50/100
58th	Lentigen 2004, Gaithersburg (United States), Acqui-Hired	Developer of lentiviral vectors for pre-clinical and clinical applications	-	Biomark Capital, HHS	29/100